Cytek Biosciences (CTKB): Debts to Book Capitalization

Cytek Biosciences, Inc. (CTKB) holds the status of a recognized expert in the field of cytometry, creating cutting-edge tools for cell analysis. This price chart illustrates the asset's dynamics, with a value of 0.11. The business is protected by exclusive patents and strict FDA oversight. The company is currently focusing on organic growth and the expansion of its sales network, temporarily eschewing mergers to preserve liquidity.

CTKB Cytek Corp Debt to Book Value Ratio (07/04/2022 - 10/27/2026)

Summary analytical data breakdowns for Cytek Biosciences Inc (CTKB)

- price and consensus price forecast:

Stock Price Cytek Biosciences, Inc.|CTKB - Broker Consensus Forecast

- market capitalization data:

Market Capitalization Cytek Corp|CTKB - Enterprise Value

- book capitalization data:

Net Assets per Single Share Cytek Biosciences|CTKB - Accounting Capitalization|Market Capitalization to Book Value Ratio cytekbio.com|CTKB - Company Total Assets

- debt and liquidity data:

Debt to Equity Cytek Biosciences, Inc.|CTKB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Cytek Bio|CTKB - Company Cumulative Debt|Debt to Book Capitalization Ratio Cytek Corp

Summary company analytics:Cytek Biosciences, Inc.

Cytek Biosciences, Inc. (CTKB) incurs high development costs for laser systems and software, necessitating precise resource management to maintain its technological leadership. An analysis of the current debt-to-capitalization ratio allows for an assessment of the proportion of borrowed capital within total asset value, where a decreasing coefficient confirms financial stability, while excessive conservatism may constrain the pace of business expansion.

Competitors of Cytek Biosciences, Inc.